PARP1 and neoplasm: In the case of olaparib, patients with BRCA-deficient ovarian or breast cancer demonstrated maximal PARP inhibition in PBMCs at doses greater than 60 mg BID olaparib capsules; however, dose-dependent anti-tumor activity was observed at higher doses of 100 and 400 mg BID olaparib capsules (26–28).